secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001549595-23-000034
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Nurix shareholders elect all director nominees; say-on-pay passes with 58.5% support
--------------------------------------------------------------------------------

- All three Class III directors elected: Sands (97.1%), Kunkel (87.5%), Silva (86.2%) of votes cast.
- Ratification of PricewaterhouseCoopers as auditor received 99.9% of votes cast for.
- Non-binding advisory say-on-pay approval: 19.9M for, 12.5M against, 1.6M abstain (58.5% support).
- Notable 12.5% of votes withheld for Kunkel and 13.8% for Silva, indicating shareholder dissent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/0001549595-23-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/nurix-20230505_8xk2023annu.htm
  HTML page:      https://secwatch.observer/filing/0001549595-23-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer